Renovare Therapeutics

Renovare Therapeutics is a private biotechnology company based in Boulder, Colorado, focused on regenerative therapies for osteoarthritis and related musculoskeletal diseases. The company formally launched in April 2026 to commercialize a portfolio of technologies developed at the University of Colorado Boulder, University of Colorado Anschutz, and Colorado State University under the ARPA-H NITRO program. Its platform combines controlled drug delivery systems, gene therapies, and regenerative biomaterials intended to restore damaged joints rather than only relieve symptoms. Renovare is advancing lead product candidates through IND-enabling work with the goal of entering first-in-human Phase 1 safety studies. The company appears to be an early-stage translational biotech built around academic innovation and non-dilutive government-backed development support.